Article Sidebar

PDF
Date Published: 21/06/2022
Abstract Views: 1223
Views PDF: 439
DOI: https://doi.org/10.51298/vmj.v514i2.2622
Issue
Vol. 514 No. 2 (2022)
Section
Các bài báo
How to Cite
Công Long, N. ., & Minh Diệp, L. . (2022). BARCELONA STAGING AND SEVERAL RISK FACTORS OF HEPATOCELLULAR CARCINOMA AT BACH MAI HOSPITAL. Vietnam Medical Journal, 514(2). https://doi.org/10.51298/vmj.v514i2.2622

BARCELONA STAGING AND SEVERAL RISK FACTORS OF HEPATOCELLULAR CARCINOMA AT BACH MAI HOSPITAL

Nguyễn Công Long1,, Lưu Minh Diệp1
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital

Main Article Content

Abstract

Objectives: Our study describes clinical, subclinical characteristics and the Barcelona (BCLC) staging of hepatocellular carcinoma (HCC) patients at Bach mai hospital from 2017 to 2019. Subjects and methods: Retrospective, cross-sectional study of 172 patients diagnosed with HCC at Bach Mai Hospital from May 2017 to May 2019. Results: the mean age of the study group was 59.9 ± 11.4 years old (from 18-86 years old) and the male/female ratio was 4.1/1. The most common symptom is abdominal pain (24.4%). The rate of hepatitis B infection in the study group was 79.7% and of hepatitis C infection was 4.1%. In our study, BCLC stage 0 accounted for 7.5%, stage A: 39.5%; B: 45.3%; C: 7.6%. The mean PIVKA-II concentration was 109.5 mAU/mL. Conclusion: It is necessary to strengthen screening for liver cancer in subjects infected with hepatitis B virus. Early screening and detection programs can also contribute to the management of HCC.

Article Details

Keywords

hepatocellular carcinoma, HCV, HBV

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
2. Bosch FX, Ribes J, Díaz M, Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl 1):S5-s16.
3. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (Baltimore, Md) 2002, 35(3):519-524.
4. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (Baltimore, Md) 2003, 37(2):429-442.
5. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D et al: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, 33(6):550-558.
6. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology 2012, 56(4):908-943.
7. Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY et al: Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointestinal endoscopy 2018, 88(2):230-239.e232.